Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Aytu Biopharma (AYTU) over the last 14 years, with Q4 2025 value amounting to -$17000.0.

  • Aytu Biopharma's Cash from Investing Activities fell 11172.41% to -$17000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$3.1 million, marking a year-over-year decrease of 79418.34%. This contributed to the annual value of -$2.6 million for FY2025, which is 67811.55% down from last year.
  • Latest data reveals that Aytu Biopharma reported Cash from Investing Activities of -$17000.0 as of Q4 2025, which was down 11172.41% from -$3.0 million recorded in Q2 2025.
  • In the past 5 years, Aytu Biopharma's Cash from Investing Activities ranged from a high of $381000.0 in Q3 2024 and a low of -$3.1 million during Q4 2021
  • Moreover, its 5-year median value for Cash from Investing Activities was -$69000.0 (2025), whereas its average is -$474421.1.
  • As far as peak fluctuations go, Aytu Biopharma's Cash from Investing Activities plummeted by 1007000.0% in 2021, and later soared by 60131.58% in 2024.
  • Over the past 5 years, Aytu Biopharma's Cash from Investing Activities (Quarter) stood at -$3.1 million in 2021, then surged by 99.84% to -$5000.0 in 2022, then plummeted by 3380.0% to -$174000.0 in 2023, then soared by 183.33% to $145000.0 in 2024, then plummeted by 111.72% to -$17000.0 in 2025.
  • Its Cash from Investing Activities was -$17000.0 in Q4 2025, compared to -$3.0 million in Q2 2025 and -$69000.0 in Q1 2025.